Teleflex to Present at the 36th Annual Piper Sandler Healthcare ConferenceWAYNE, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE:
TFX), is scheduled to speak at the 36th Annual Piper Sandler Healthcare Conference at The Lotte New York Palace, New York, NY, on Tuesday, December 3, 2024, at 9:30 a.m. (ET).
Teleflex to Present at the Jefferies London Healthcare ConferenceWAYNE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE:
TFX), is scheduled to speak at the Jefferies London Healthcare Conference, on Thursday, November 21, 2024, at 9:30 a.m. (GMT).
Teleflex Announces Quarterly DividendWAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:
TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 16, 2024, to shareholders of record at the close of business on November 15, 2024.
Teleflex Reports Third Quarter Financial Results and Full Year 2024 OutlookWAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:
TFX) (the “Company”) today announced financial results for the third quarter ended September 29, 2024.
First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT)Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after prostatectomy.
New Data Presented at ASTRO 2024 Further Demonstrate the Safety and Efficacy of Barrigel™ Rectal Spacer, the First and Only Sculptable Hyaluronic Acid Rectal Spacer, in Patients Undergoing Radiation Therapy for Prostate Cancer(1-3)• Barrigel™ rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy, with an excellent toxicity and safety profile; and low incidence (0.32-1%) of rectal wall infiltration (RWI), which can be safely reversed using hyaluronidase4,5
Teleflex Announces Third Quarter 2024 Earnings Conference Call InformationWAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:
TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 31, 2024.
Teleflex™ Chooses o9’s AI-Powered Platform for End-to-End Integrated Business Planning and Supply Chain Management
o9, a leading enterprise AI software platform provider for transforming planning and decision-making, today announced that Teleflex Incorporated (NYSE:
TFX), a leading global provider of medical technologies, has selected o9 to help enhance its end-to-end integrated business planning and supply chain management capabilities. This partnership includes o9’s Demand Planning, Supply Planning, and Integrated Business Planning (IBP) technologies.
Teleflex to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceWAYNE, Pa., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE:
TFX), is scheduled to speak at the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York, on Friday, September 6, 2024, at 7:45 a.m. (ET).
Teleflex Announces Publication of a Propensity Matching Review of Retrospective Data Reporting that the Titan SGS™ Stapler Enables Consistent Gastric Pouch Formation with Fewer Variations, Providing Potentially Enhanced Clinical Outcomes and SignificantWAYNE, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:
TFX), a leading global provider of medical technologies, today announced the publication of a new retrospective analysis of clinical data linking the Titan SGS™ Stapler with enhanced clinical outcomes and significant procedural efficiency benefits compared with multi-fire surgical staplers in patients undergoing laparoscopic sleeve gastrectomy (LSG).1 The study was conducted by five surgeons at a Corewell Health Hospital in Grand Rapids, MI, an MBSAQIP-accredited facility that is a Center of Excellence for bariatric surgery.* The study results appear in the current issue of Obesity Surgery.1
Teleflex Announces Quarterly DividendWAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:
TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024.
Teleflex Reports Second Quarter Financial Results and Full Year 2024 OutlookAnnounces $500 million share repurchase authorization inclusive of a $200 million accelerated share repurchase of common stock
Teleflex Expands Interventional Cardiology Portfolio with FDA 510(k) Clearance of the Ringer™ Perfusion Balloon CatheterThis milestone highlights Teleflex’s commitment to providing interventionalists with new tools specifically engineered to address unmet clinical needs.
Teleflex Awarded Hemostasis Products Agreements with Premier, Inc.Hemostatic Dressings and Devices are Now Available at Special Pricing for Premier Members
Teleflex Announces the Teleflex Center for Antimicrobial ProtectionWAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:
TFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives.
Teleflex Announces Second Quarter 2024 Earnings Conference Call InformationWAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:
TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024.
